lilly oral glp-1 Eli Pill, Orfoglipron Shows Strong Phase 3 Results Eli Lilly stock soars on

Trulicity is given as a once-weekly injection using a single-use pen

Additionally, in a phase 2 trial targeting type 2 diabetes, retatrutide demonstrated significant improvements in glycemic control and substantial weight reduction, maintaining a safety profile comparable to certain approved GLP-1RAs 8 (Supplementary Table S1)

As we look to 2026, the story becomes one of defining firsts: the debut of oral GLP-1s, the first loss of exclusivity for a GLP-1 receptor antagonist, and landmark coverage decisions such as obesity medications entering Medicare formularies for obesity as a standalone indication

Studies have shown these drugs lower the risk of a cardiac event such as a heart attack or stroke

The symptoms we just mentioned are just the tip of the iceberg

In practice, this portion of the formula is likely supportive rather than central to its effects